TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33079259

Group type: EXPERIMENTAL
Intervention: Osteosarcopenic obesity (OSO)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Lower handgrip strength
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Appendicular lean mass index (ALMi)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 460
Study: 33079376

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 62
Study: 33079774

Group type: EXPERIMENTAL
Intervention: Moderately disproportioned GAP score category
Number of subjects: 159

Group type: COMPARATOR
Intervention: Higher GAP score
Number of subjects: 159
Study: 33079873

Group type: EXPERIMENTAL
Intervention: Recirculatory model
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gated recurrent unit neural network with ensemble learning
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4-compartment model
Number of subjects: 30
Study: 33079880

Group type: EXPERIMENTAL
Intervention: LMA Gastro™
Number of subjects: 30
Study: 33080003

Group type: EXPERIMENTAL
Intervention: IFC-ACS lesions
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Endothelial cells in disturbed laminar flow conditions
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: CD8+ T cells and their cytotoxic effector molecules
Number of subjects: 170
Study: 33080007

Group type: EXPERIMENTAL
Intervention: Flow cytometry using the ΔN technique
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Morphologic definition of persistent disease (>15% AML)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Patients not achieving morphologic remission (>5% blasts)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: ΔN technique
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Detection of abnormal myeloid progenitor cells by ΔN
Number of subjects: 784
Study: 33080806

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study: 33080911

Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine (T-DM1) as second-line therapy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine (T-DM1) as third-line therapy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine (T-DM1) as fourth-line therapy or higher
Number of subjects: 76
Study: 33081973

Group type: EXPERIMENTAL
Intervention: Self-reported functional capacity less than two flights of stairs
Number of subjects: 4560

Group type: EXPERIMENTAL
Intervention: Self-reported functional capacity plus revised cardiac risk index (RCRI)
Number of subjects: 4560
Study: 33082173

Group type: EXPERIMENTAL
Intervention: Newly diagnosed diabetes (NDD)
Number of subjects: 3501

Group type: COMPARATOR
Intervention: Established diabetes
Number of subjects: 3501

Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 3501
Study: 33082193

Group type: EXPERIMENTAL
Intervention: CAVI measured by VOPITB
Number of subjects: 120

Group type: COMPARATOR
Intervention: CAVI measured by VaSera VS-1500
Number of subjects: 120
Study: 33082208

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 0
Study: 33082311

Group type: EXPERIMENTAL
Intervention: Deep breaths
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Bursts
Number of subjects: 440
Study: 33082372

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) therapy, duration shortened in 11 of the 29 patients (38%)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir for 6 weeks
Number of subjects: 29
Study: 33083026

Group type: EXPERIMENTAL
Intervention: Ad26 vector-based vaccine (Ad26.COV2.S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33083050

Group type: EXPERIMENTAL
Intervention: Short-term perfluoro-n-octane (PFO) with perfluoropropane (C3F8) gas
Number of subjects: 30
Study: 33083561

Group type: EXPERIMENTAL
Intervention: Metformin as adjunctive therapy
Number of subjects: 0
Study: 33083661

Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT) reirradiation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prior surgery
Number of subjects: 45
Study: 33083685

Group type: EXPERIMENTAL
Intervention: Remote, real-time activity-monitoring devices combined with daily electronic patient-reported outcome (ePRO) items.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard HF assessment (e.g., 6-min walking distance [6MWD], blood biomarkers, Kansas City Cardiomyopathy Questionnaire [KCCQ], and echocardiography).
Number of subjects: 80
Study: 33083813

Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor (Reveal XT, Reveal Linq) implanted before hospital discharge with continuous monitoring for up to 2 years.
Number of subjects: 103
Study: 33083823

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (Group 1)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Non-operated women (Group 2)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Non-operated severely obese women (Group 3)
Number of subjects: 83
Study: 33083853

Group type: EXPERIMENTAL
Intervention: Passeo-18 lx drug-coated balloon
Number of subjects: 877
Study: 33083869

Group type: EXPERIMENTAL
Intervention: CMR-FT-derived remote circumferential strain (CS)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: RM CS cutoff value of -25.8%
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Impaired RM CS
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: RM CS in patients with reduced LVEF ≤ 35%
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: RM CS in patients with reduced GCS > -18.3%
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: RM CS in patients with large microvascular obstruction ≥ 1.46%
Number of subjects: 1034
Study: 33084020

Group type: EXPERIMENTAL
Intervention: Platinum-containing chemotherapy regimens
Number of subjects: 1349

Group type: COMPARATOR
Intervention: Non-platinum chemotherapy regimens
Number of subjects: 1349
Study: 33084175

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 88
Study: 33084183

Group type: EXPERIMENTAL
Intervention: PARP inhibitors
Number of subjects: 0
Study: 33084502

Group type: EXPERIMENTAL
Intervention: Zilver PTX drug-eluting stent (DES)
Number of subjects: 0
Study: 33084588

Group type: EXPERIMENTAL
Intervention: Hospital-Community-Family-Based Telemedicine (HCFT-AF) program
Number of subjects: 73
Study: 33084880

Group type: EXPERIMENTAL
Intervention: Torasemide, 5 mg daily for 16 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (AA genotype of the SNP rs13333226)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (G allele)
Number of subjects: 240
Study: 33084938

Group type: EXPERIMENTAL
Intervention: FDOPA-PET parameters (maximum and mean lesion standardised uptake values [SUV] and ratios)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: FDOPA-PET uptake interpretation
Number of subjects: 74
Study: 33085593

Group type: EXPERIMENTAL
Intervention: Allogeneic eye drops from cord blood platelet lysate (CBED), 1-2 drops to the affected eye four to six times per day for 19 days, median of 19 vials (range 19-442).
Number of subjects: 33
Study: 33085815

Group type: EXPERIMENTAL
Intervention: MicroRNAs (miRNAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-type lectin receptors (CLRs)
Number of subjects: 0
Study: 33085860

Group type: EXPERIMENTAL
Intervention: Dasatinib plus glucocorticoids followed by two cycles of blinatumomab
Number of subjects: 63
Study: 33086159

Group type: EXPERIMENTAL
Intervention: pembrolizumab plus standard-of-care (SOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard-of-care (SOC)
Number of subjects: 0
Study: 33086312

Group type: EXPERIMENTAL
Intervention: Low aFXa levels (initial low aFXa)
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Twice daily enoxaparin
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Once daily enoxaparin
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: High aFXa levels
Number of subjects: 985
Study: 33086913

Group type: EXPERIMENTAL
Intervention: Smartphone application for data collection
Number of subjects: 2000
Study: 33087092

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 213
Study: 33087116

Group type: EXPERIMENTAL
Intervention: Iron deficiency
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Inflammation markers
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Hyperferritinemia
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Severe lung pathologies
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Performance status
Number of subjects: 109
Study: 33087142

Group type: EXPERIMENTAL
Intervention: Oral supplementation with a fractionated marine lipid concentration standardized to 17-HDHA and 18-HEPE for 4 weeks
Number of subjects: 44
Study: 33087171

Group type: EXPERIMENTAL
Intervention: K-means clustering algorithm for cognitive phenotypes
Number of subjects: 156

Group type: COMPARATOR
Intervention: Classical approach of cognitive impairment assessment
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Opioid treatment
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Demographic and clinical variables
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Cognitive reserve
Number of subjects: 156
Study: 33087150

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 301
Study: 33087333

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg (for bodyweight ≥50 kg) or 3 mg/kg (for bodyweight <50 kg) every 2 weeks plus oral apatinib 250 mg daily
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 190
Study: 33087340

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-enabled diabetic retinopathy screening using a deep learning algorithm
Number of subjects: 47269

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-enabled diabetic retinopathy screening
Number of subjects: 47269
Study: 33087345

Group type: EXPERIMENTAL
Intervention: nTreg infusion (0.5, 1.0, or 2.5-3.0×10^6 cells)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Reference group (standard dual or triple drug immunosuppression)
Number of subjects: 11
Study: 33087380

Group type: EXPERIMENTAL
Intervention: Diet, inflammatory, genetic, microbiome and metabolomic profiles in patients with IBS and IBD
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Active disease
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Psychological comorbidity
Number of subjects: 8000
Study: 33087451

Group type: EXPERIMENTAL
Intervention: Students 4 Best Evidence (S4BE) platform as a digital Problem-Based Learning (DPBL) method
Number of subjects: 121
Study: 33087548

Group type: EXPERIMENTAL
Intervention: Low-dose CT lung cancer screening (LDCT)
Number of subjects: 787

Group type: COMPARATOR
Intervention: Community sample
Number of subjects: 787
Study: 33087746

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (3 hours sleep opportunity at the end of night)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Full sleep condition
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation
Number of subjects: 69
Study: 33088015

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 498
Study: 33088573

Group type: EXPERIMENTAL
Intervention: PBMT-sMF (photobiomodulation therapy combined with static magnetic field)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PBMT-sMF
Number of subjects: 60
Study: 33088581

Group type: EXPERIMENTAL
Intervention: 6-week cooking intervention delivered at a community kitchen setting
Number of subjects: 0
Study: 33089005

Group type: EXPERIMENTAL
Intervention: Sustained release transdermal nicotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study: 33089069

Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 25
Study: 33089304

Group type: EXPERIMENTAL
Intervention: CDR132L (monthly intravenous treatments over 3 or 5 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 33089492

Group type: COMPARATOR
Intervention: Educational interventions
Number of subjects: 2832

Group type: COMPARATOR
Intervention: Behavioural interventions (intensive reminders)
Number of subjects: 2832

Group type: COMPARATOR
Intervention: Mixed interventions
Number of subjects: 2832

Group type: COMPARATOR
Intervention: Various interventions (including educational and behavioural)
Number of subjects: 2832

Group type: COMPARATOR
Intervention: Self-efficacy and quality of life interventions
Number of subjects: 2832
Study: 33089502

Group type: EXPERIMENTAL
Intervention: Renin inhibitors (RIs)
Number of subjects: 13627

Group type: COMPARATOR
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 13627
Study: 33089593

Group type: EXPERIMENTAL
Intervention: 8 weeks of treatment for bipolar disorder
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy comparison group (n=41)
Number of subjects: 42
Study: 33089824

Group type: EXPERIMENTAL
Intervention: MCC-IMS (multicapillary column coupled ion mobility spectrometry)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy staff and patients with negative PCR)
Number of subjects: 24
Study: 33089874

Group type: EXPERIMENTAL
Intervention: Pevonedistat (TAK-924/MLN4924)
Number of subjects: 0
Study: 33089892

Group type: EXPERIMENTAL
Intervention: Portosystemic shunts (TS, DSRS, TIPS)
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: TS
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: DSRS
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 1828
Study: 33090077

Group type: EXPERIMENTAL
Intervention: Abdominal fixation under sedation and local or epidural anesthesia
Number of subjects: 10
Study: 33090333

Group type: EXPERIMENTAL
Intervention: Cetuximab (loading dose followed by weekly infusions of 250 mg/m2)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 49
Study: 33090368

Group type: EXPERIMENTAL
Intervention: Conditioned fear task and magnetoencephalography to record pain-related fear responses in FM patients.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pregabalin treatment in FM patients.
Number of subjects: 52
Study: 33090970

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 3408

Group type: COMPARATOR
Intervention: Lamivudine (LAM)
Number of subjects: 3408
Study: 33091124

Group type: EXPERIMENTAL
Intervention: Cord blood (CB)-derived adoptive cell therapy after salvage chemotherapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cord blood (CB)-derived adoptive cell therapy
Number of subjects: 31
Study: 33091791

Group type: EXPERIMENTAL
Intervention: Child-friendly 3D bimanual protocol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Typically developing children (TDC)
Number of subjects: 20
Study: 33091843

Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention
Number of subjects: 67
Study: 33091844

Group type: EXPERIMENTAL
Intervention: Naloxone units distributed in HCS communities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDA-approved buprenorphine products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-risk opioid prescribing incidents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid overdose deaths
Number of subjects: 0
Study: 33091842

Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overdose education and naloxone distribution (OEND)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder (MOUD)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Safer opioid analgesic prescribing
Number of subjects: 67
Study: 33091891

Group type: EXPERIMENTAL
Intervention: Bioelectric neural interface
Number of subjects: 0
Study: 33092403

Group type: EXPERIMENTAL
Intervention: Ibrutinib treatment for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acalabrutinib treatment for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac-specific Csk knockout in mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kinase inhibitors blocking Csk
Number of subjects: 0
Study: 33092438

Group type: COMPARATOR
Intervention: hs-CRP level <1.0 mg/L
Number of subjects: 2018

Group type: EXPERIMENTAL
Intervention: hs-CRP level
Number of subjects: 2018
Study: 33092570

Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 398
Study: 33092588

Group type: EXPERIMENTAL
Intervention: Patients with non-ischemic LGE lesions
Number of subjects: 296
Study: 33092646

Group type: EXPERIMENTAL
Intervention: Weight loss treatment including Very Low Energy Diet (VLED)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Weight loss treatment
Number of subjects: 41
Study: 33092709

Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 109
Study: 33093033

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 testing via nasopharyngeal swab using reverse-transcriptase PCR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demographic and clinical data collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate modelling
Number of subjects: 0
Study: 33093193

Group type: EXPERIMENTAL
Intervention: Phosphorus magnetic resonance spectroscopy during hemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphorus magnetic resonance spectroscopy examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphorus magnetic resonance spectroscopy
Number of subjects: 0
Study: 33093337

Group type: EXPERIMENTAL
Intervention: Small molecule poly-ADP-ribosyl polymerase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel with immune checkpoint inhibitor antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 0
Study: 33093408

Group type: EXPERIMENTAL
Intervention: Imlifidase treatment
Number of subjects: 0
Study: 33093900

Group type: EXPERIMENTAL
Intervention: Intravitreal administration of bevacizumab (Lumiere)
Number of subjects: 0
Study: 33094311

Group type: COMPARATOR
Intervention: PURE EP™ (PEP) system
Number of subjects: 10
Study: 33094357

Group type: EXPERIMENTAL
Intervention: New patient-reported outcome measure (PROM) for financial toxicity (FT)
Number of subjects: 34
Study: 33094474

Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy (400 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab (400 mg/day)
Number of subjects: 12
Study: 33094498

Group type: EXPERIMENTAL
Intervention: Indocyanine green
Number of subjects: 88

Group type: COMPARATOR
Intervention: 99m Technetium (radioisotope)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combined method (Indocyanine green and 99m Technetium)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Indocyanine green and 99m Technetium
Number of subjects: 88
Study: 33094734

Group type: EXPERIMENTAL
Intervention: EPIO app-based cognitive-behavioral pain self-management intervention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EPIO intervention
Number of subjects: 50
Study: 33094826

Group type: EXPERIMENTAL
Intervention: LiDCO CNAP (continuous non-invasive arterial pressure) device
Number of subjects: 104
Study: 33095075

Group type: EXPERIMENTAL
Intervention: POCP visual impression of malignancy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: POCP-guided samples histological analysis
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Technical success for lesion visualization
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Median VAS scores for insertions in bile and PD
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Median VAS score for access to the lesion
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Median VAS score for image quality
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 30-day complications
Number of subjects: 66
Study: 33095117

Group type: EXPERIMENTAL
Intervention: Fludarabine-based therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C/CHOP-based therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil-based therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapies (kinase inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 0
Study: 33095287

Group type: EXPERIMENTAL
Intervention: Crizotinib at 215 mg/m² in combination with cyclophosphamide and topotecan
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Crizotinib at 165 mg/m² and 280 mg/m²
Number of subjects: 44
Study: 33095411

Group type: EXPERIMENTAL
Intervention: XC8 2 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: XC8 10 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: XC8 100 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 33095458

Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment
Number of subjects: 1563
Study: 33095645

Group type: EXPERIMENTAL
Intervention: E-cigarette users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 33095832

Group type: EXPERIMENTAL
Intervention: Social health
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Physical health
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: PTSS
Number of subjects: 598
Study: 33095874

Group type: EXPERIMENTAL
Intervention: 64Cu-daratumumab PET/CT
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unlabeled daratumumab (0 mg, 10 mg, 45 mg, 95 mg)
Number of subjects: 12
Study: 33096421

Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m²
Number of subjects: 20
Study: 33096476

Group type: EXPERIMENTAL
Intervention: Chemo-radiation treatment
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Protein expression data by RPPA
Number of subjects: 89
Study: 33097085

Group type: EXPERIMENTAL
Intervention: CR-CHOP (tucidinostat plus R-CHOP)
Number of subjects: 49
Study: 33097369

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided radial artery cannulation
Number of subjects: 680
Study: 33097612

Group type: EXPERIMENTAL
Intervention: Emactuzumab (500 to 1000 mg) and Selicrelumab (2 to 16 mg) administered intravenously every 3 weeks
Number of subjects: 0